February 23, 2016

New Strategies for Effective Therapeutics in Critically Ill Patients

Author Affiliations
  • 1Department of Medicine, University of California, San Francisco
  • 2Cardiovascular Research Institute, University of California, San Francisco
  • 3Division of Nephrology, University of California, San Francisco

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2016;315(8):747-748. doi:10.1001/jama.2016.0661

Over the past 25 years, considerable therapeutic success has been achieved in several areas of clinical medicine, including childhood cancer, some adult cancers, human immunodeficiency virus, and chronic liver disease. However, with the notable exception of surfactant therapy for infant respiratory distress syndrome, there has been limited success in the application of novel therapeutics to improve clinical outcomes in critically ill patients. This leads to the following questions: Why have so many pharmacological and other therapeutics failed in critically ill patients? What are the prospects for effective new therapies? and What can be done to increase the chance of success in the future?

First Page Preview View Large
First page PDF preview
First page PDF preview